HLA-A02:01 allele is associated with tanshinone-induced cutaneous drug reactions in Chinese population
Tanshinone, a widely used Chinese patent medicine, has been confirmed to have various kinds of pharmacological effects although frequently causing cutaneous adverse drug reactions (cADRs). We aim to identify whether human leukocyte antigen (HLA) class I alleles are associated with tanshinone-induced...
Gespeichert in:
| Veröffentlicht in: | The pharmacogenomics journal 2020-06, Vol.20 (3), p.408-414 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 414 |
|---|---|
| container_issue | 3 |
| container_start_page | 408 |
| container_title | The pharmacogenomics journal |
| container_volume | 20 |
| creator | Zhu, Qinyuan Zhang, Yanzhou Xuan, Jiekun Yang, Fanping Du, Binbin Chen, Sheng-an Yan, Sijia Jiang, Menglin Zhu, Huizhong Xiong, Hao Luo, Xiaoqun Xing, Qinghe |
| description | Tanshinone, a widely used Chinese patent medicine, has been confirmed to have various kinds of pharmacological effects although frequently causing cutaneous adverse drug reactions (cADRs). We aim to identify whether human leukocyte antigen (HLA) class I alleles are associated with tanshinone-induced cADRs in Han Chinese. The association study including 18 patients with tanshinone-induced cADRs, 67 tanshinone-tolerant volunteers, and two general population databases consisted of 10,689 and 169,995 healthy subjects was performed. The frequency of tanshinone-induced cADRs patients carrying
HLA-A*02:01
was significantly higher when compared with the general control groups (OR = 6.25, Pc = 7.20 × 10
−5
; OR = 7.14, Pc = 8.00 × 10
−6
), and with the tolerant group (OR = 5.09, Pc = 0.024). The molecular docking assay confirmed high affinity of the ingredients of tanshinone towards
HLA-A*02:01
(≤−7.5 kcal/mol). The result suggested
HLA-A*02:01
may work as a promisingly predictive marker for tanshinone personalized therapy in Han Chinese. |
| doi_str_mv | 10.1038/s41397-019-0121-1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2320873676</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A625089834</galeid><sourcerecordid>A625089834</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-d40493640c0cc20e75d6359f0fd3ae3866244851a14e50ef5ab7ba5ce504bb2a3</originalsourceid><addsrcrecordid>eNp9kk2LFDEQhhtR3HX1B3iRgBcvvVblo5P2NgzqCgNeFLyFdLp6NktPeky6Wfz3ZuzVRVEJIUnleSuV5K2q5wiXCMK8zhJFq2vAtnSONT6ozlFqUSMqePhjDjVv2i9n1ZOcbwCwQW0eV2cCdcuFhvNquNpt6g3wN4DMjSONxEJmLufJBzdTz27DfM1mF_N1iFOkOsR-8SXulxKkacmsT8ueJXJ-DlPMLES2LSxlYsfpuIzuFH5aPRrcmOnZ3XhRfX739tP2qt59fP9hu9nVXmI7170E2YpGggfvOZBWfSNUO8DQC0fCNA2X0ih0KEkBDcp1unPKl4XsOu7ERfVqzXtM09eF8mwPIXsax7VWywUHo0Wjm4K-_AO9mZYUS3WWS10SKmPM_ynQAqFFdU_t3Ug2xGGak_Ono-2m4QpMa4Qs1OVfqNJ6OgRfHncIJf6bAFeBT1POiQZ7TOHg0jeLYE8OsKsDbHGAPTnAYtG8uCt46Q7U_1L8_PIC8BXIZSvuKd3f6N9ZvwPcFLfh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2407310915</pqid></control><display><type>article</type><title>HLA-A02:01 allele is associated with tanshinone-induced cutaneous drug reactions in Chinese population</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Zhu, Qinyuan ; Zhang, Yanzhou ; Xuan, Jiekun ; Yang, Fanping ; Du, Binbin ; Chen, Sheng-an ; Yan, Sijia ; Jiang, Menglin ; Zhu, Huizhong ; Xiong, Hao ; Luo, Xiaoqun ; Xing, Qinghe</creator><creatorcontrib>Zhu, Qinyuan ; Zhang, Yanzhou ; Xuan, Jiekun ; Yang, Fanping ; Du, Binbin ; Chen, Sheng-an ; Yan, Sijia ; Jiang, Menglin ; Zhu, Huizhong ; Xiong, Hao ; Luo, Xiaoqun ; Xing, Qinghe</creatorcontrib><description>Tanshinone, a widely used Chinese patent medicine, has been confirmed to have various kinds of pharmacological effects although frequently causing cutaneous adverse drug reactions (cADRs). We aim to identify whether human leukocyte antigen (HLA) class I alleles are associated with tanshinone-induced cADRs in Han Chinese. The association study including 18 patients with tanshinone-induced cADRs, 67 tanshinone-tolerant volunteers, and two general population databases consisted of 10,689 and 169,995 healthy subjects was performed. The frequency of tanshinone-induced cADRs patients carrying
HLA-A*02:01
was significantly higher when compared with the general control groups (OR = 6.25, Pc = 7.20 × 10
−5
; OR = 7.14, Pc = 8.00 × 10
−6
), and with the tolerant group (OR = 5.09, Pc = 0.024). The molecular docking assay confirmed high affinity of the ingredients of tanshinone towards
HLA-A*02:01
(≤−7.5 kcal/mol). The result suggested
HLA-A*02:01
may work as a promisingly predictive marker for tanshinone personalized therapy in Han Chinese.</description><identifier>ISSN: 1470-269X</identifier><identifier>EISSN: 1473-1150</identifier><identifier>DOI: 10.1038/s41397-019-0121-1</identifier><identifier>PMID: 31792370</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>45/23 ; 45/77 ; 631/154/1438 ; 631/208/205 ; Abietanes - adverse effects ; Acne ; Adolescent ; Adult ; Adverse and side effects ; Aged ; Alleles ; Angina pectoris ; Anti-Infective Agents - adverse effects ; Antigens ; Asian Continental Ancestry Group - genetics ; Biomedical and Life Sciences ; Biomedicine ; Causes of ; Chinese medicine ; Complications and side effects ; Dermatology ; Drug Eruptions - diagnosis ; Drug Eruptions - genetics ; Drugs ; Female ; Gene Expression ; Genetic aspects ; Genetic Association Studies - methods ; Health aspects ; Histocompatibility antigen HLA ; Histocompatibility antigens ; HLA histocompatibility antigens ; HLA-A2 Antigen - genetics ; Hospitals ; Human Genetics ; Humans ; Ingredients ; Ligands ; Male ; Middle Aged ; Molecular Docking Simulation - methods ; Oncology ; Pharmacogenetics ; Pharmacology, Experimental ; Pharmacotherapy ; Population ; Population genetics ; Population Surveillance - methods ; Psychopharmacology ; Skin diseases ; Software ; Staphylococcus infections ; Tanshinones ; Young Adult</subject><ispartof>The pharmacogenomics journal, 2020-06, Vol.20 (3), p.408-414</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2019</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c419t-d40493640c0cc20e75d6359f0fd3ae3866244851a14e50ef5ab7ba5ce504bb2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31792370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Qinyuan</creatorcontrib><creatorcontrib>Zhang, Yanzhou</creatorcontrib><creatorcontrib>Xuan, Jiekun</creatorcontrib><creatorcontrib>Yang, Fanping</creatorcontrib><creatorcontrib>Du, Binbin</creatorcontrib><creatorcontrib>Chen, Sheng-an</creatorcontrib><creatorcontrib>Yan, Sijia</creatorcontrib><creatorcontrib>Jiang, Menglin</creatorcontrib><creatorcontrib>Zhu, Huizhong</creatorcontrib><creatorcontrib>Xiong, Hao</creatorcontrib><creatorcontrib>Luo, Xiaoqun</creatorcontrib><creatorcontrib>Xing, Qinghe</creatorcontrib><title>HLA-A02:01 allele is associated with tanshinone-induced cutaneous drug reactions in Chinese population</title><title>The pharmacogenomics journal</title><addtitle>Pharmacogenomics J</addtitle><addtitle>Pharmacogenomics J</addtitle><description>Tanshinone, a widely used Chinese patent medicine, has been confirmed to have various kinds of pharmacological effects although frequently causing cutaneous adverse drug reactions (cADRs). We aim to identify whether human leukocyte antigen (HLA) class I alleles are associated with tanshinone-induced cADRs in Han Chinese. The association study including 18 patients with tanshinone-induced cADRs, 67 tanshinone-tolerant volunteers, and two general population databases consisted of 10,689 and 169,995 healthy subjects was performed. The frequency of tanshinone-induced cADRs patients carrying
HLA-A*02:01
was significantly higher when compared with the general control groups (OR = 6.25, Pc = 7.20 × 10
−5
; OR = 7.14, Pc = 8.00 × 10
−6
), and with the tolerant group (OR = 5.09, Pc = 0.024). The molecular docking assay confirmed high affinity of the ingredients of tanshinone towards
HLA-A*02:01
(≤−7.5 kcal/mol). The result suggested
HLA-A*02:01
may work as a promisingly predictive marker for tanshinone personalized therapy in Han Chinese.</description><subject>45/23</subject><subject>45/77</subject><subject>631/154/1438</subject><subject>631/208/205</subject><subject>Abietanes - adverse effects</subject><subject>Acne</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Adverse and side effects</subject><subject>Aged</subject><subject>Alleles</subject><subject>Angina pectoris</subject><subject>Anti-Infective Agents - adverse effects</subject><subject>Antigens</subject><subject>Asian Continental Ancestry Group - genetics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Causes of</subject><subject>Chinese medicine</subject><subject>Complications and side effects</subject><subject>Dermatology</subject><subject>Drug Eruptions - diagnosis</subject><subject>Drug Eruptions - genetics</subject><subject>Drugs</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Genetic aspects</subject><subject>Genetic Association Studies - methods</subject><subject>Health aspects</subject><subject>Histocompatibility antigen HLA</subject><subject>Histocompatibility antigens</subject><subject>HLA histocompatibility antigens</subject><subject>HLA-A2 Antigen - genetics</subject><subject>Hospitals</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Ingredients</subject><subject>Ligands</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Molecular Docking Simulation - methods</subject><subject>Oncology</subject><subject>Pharmacogenetics</subject><subject>Pharmacology, Experimental</subject><subject>Pharmacotherapy</subject><subject>Population</subject><subject>Population genetics</subject><subject>Population Surveillance - methods</subject><subject>Psychopharmacology</subject><subject>Skin diseases</subject><subject>Software</subject><subject>Staphylococcus infections</subject><subject>Tanshinones</subject><subject>Young Adult</subject><issn>1470-269X</issn><issn>1473-1150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kk2LFDEQhhtR3HX1B3iRgBcvvVblo5P2NgzqCgNeFLyFdLp6NktPeky6Wfz3ZuzVRVEJIUnleSuV5K2q5wiXCMK8zhJFq2vAtnSONT6ozlFqUSMqePhjDjVv2i9n1ZOcbwCwQW0eV2cCdcuFhvNquNpt6g3wN4DMjSONxEJmLufJBzdTz27DfM1mF_N1iFOkOsR-8SXulxKkacmsT8ueJXJ-DlPMLES2LSxlYsfpuIzuFH5aPRrcmOnZ3XhRfX739tP2qt59fP9hu9nVXmI7170E2YpGggfvOZBWfSNUO8DQC0fCNA2X0ih0KEkBDcp1unPKl4XsOu7ERfVqzXtM09eF8mwPIXsax7VWywUHo0Wjm4K-_AO9mZYUS3WWS10SKmPM_ynQAqFFdU_t3Ug2xGGak_Ono-2m4QpMa4Qs1OVfqNJ6OgRfHncIJf6bAFeBT1POiQZ7TOHg0jeLYE8OsKsDbHGAPTnAYtG8uCt46Q7U_1L8_PIC8BXIZSvuKd3f6N9ZvwPcFLfh</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Zhu, Qinyuan</creator><creator>Zhang, Yanzhou</creator><creator>Xuan, Jiekun</creator><creator>Yang, Fanping</creator><creator>Du, Binbin</creator><creator>Chen, Sheng-an</creator><creator>Yan, Sijia</creator><creator>Jiang, Menglin</creator><creator>Zhu, Huizhong</creator><creator>Xiong, Hao</creator><creator>Luo, Xiaoqun</creator><creator>Xing, Qinghe</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20200601</creationdate><title>HLA-A02:01 allele is associated with tanshinone-induced cutaneous drug reactions in Chinese population</title><author>Zhu, Qinyuan ; Zhang, Yanzhou ; Xuan, Jiekun ; Yang, Fanping ; Du, Binbin ; Chen, Sheng-an ; Yan, Sijia ; Jiang, Menglin ; Zhu, Huizhong ; Xiong, Hao ; Luo, Xiaoqun ; Xing, Qinghe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-d40493640c0cc20e75d6359f0fd3ae3866244851a14e50ef5ab7ba5ce504bb2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>45/23</topic><topic>45/77</topic><topic>631/154/1438</topic><topic>631/208/205</topic><topic>Abietanes - adverse effects</topic><topic>Acne</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Adverse and side effects</topic><topic>Aged</topic><topic>Alleles</topic><topic>Angina pectoris</topic><topic>Anti-Infective Agents - adverse effects</topic><topic>Antigens</topic><topic>Asian Continental Ancestry Group - genetics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Causes of</topic><topic>Chinese medicine</topic><topic>Complications and side effects</topic><topic>Dermatology</topic><topic>Drug Eruptions - diagnosis</topic><topic>Drug Eruptions - genetics</topic><topic>Drugs</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Genetic aspects</topic><topic>Genetic Association Studies - methods</topic><topic>Health aspects</topic><topic>Histocompatibility antigen HLA</topic><topic>Histocompatibility antigens</topic><topic>HLA histocompatibility antigens</topic><topic>HLA-A2 Antigen - genetics</topic><topic>Hospitals</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Ingredients</topic><topic>Ligands</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Molecular Docking Simulation - methods</topic><topic>Oncology</topic><topic>Pharmacogenetics</topic><topic>Pharmacology, Experimental</topic><topic>Pharmacotherapy</topic><topic>Population</topic><topic>Population genetics</topic><topic>Population Surveillance - methods</topic><topic>Psychopharmacology</topic><topic>Skin diseases</topic><topic>Software</topic><topic>Staphylococcus infections</topic><topic>Tanshinones</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Qinyuan</creatorcontrib><creatorcontrib>Zhang, Yanzhou</creatorcontrib><creatorcontrib>Xuan, Jiekun</creatorcontrib><creatorcontrib>Yang, Fanping</creatorcontrib><creatorcontrib>Du, Binbin</creatorcontrib><creatorcontrib>Chen, Sheng-an</creatorcontrib><creatorcontrib>Yan, Sijia</creatorcontrib><creatorcontrib>Jiang, Menglin</creatorcontrib><creatorcontrib>Zhu, Huizhong</creatorcontrib><creatorcontrib>Xiong, Hao</creatorcontrib><creatorcontrib>Luo, Xiaoqun</creatorcontrib><creatorcontrib>Xing, Qinghe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The pharmacogenomics journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Qinyuan</au><au>Zhang, Yanzhou</au><au>Xuan, Jiekun</au><au>Yang, Fanping</au><au>Du, Binbin</au><au>Chen, Sheng-an</au><au>Yan, Sijia</au><au>Jiang, Menglin</au><au>Zhu, Huizhong</au><au>Xiong, Hao</au><au>Luo, Xiaoqun</au><au>Xing, Qinghe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HLA-A02:01 allele is associated with tanshinone-induced cutaneous drug reactions in Chinese population</atitle><jtitle>The pharmacogenomics journal</jtitle><stitle>Pharmacogenomics J</stitle><addtitle>Pharmacogenomics J</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>20</volume><issue>3</issue><spage>408</spage><epage>414</epage><pages>408-414</pages><issn>1470-269X</issn><eissn>1473-1150</eissn><abstract>Tanshinone, a widely used Chinese patent medicine, has been confirmed to have various kinds of pharmacological effects although frequently causing cutaneous adverse drug reactions (cADRs). We aim to identify whether human leukocyte antigen (HLA) class I alleles are associated with tanshinone-induced cADRs in Han Chinese. The association study including 18 patients with tanshinone-induced cADRs, 67 tanshinone-tolerant volunteers, and two general population databases consisted of 10,689 and 169,995 healthy subjects was performed. The frequency of tanshinone-induced cADRs patients carrying
HLA-A*02:01
was significantly higher when compared with the general control groups (OR = 6.25, Pc = 7.20 × 10
−5
; OR = 7.14, Pc = 8.00 × 10
−6
), and with the tolerant group (OR = 5.09, Pc = 0.024). The molecular docking assay confirmed high affinity of the ingredients of tanshinone towards
HLA-A*02:01
(≤−7.5 kcal/mol). The result suggested
HLA-A*02:01
may work as a promisingly predictive marker for tanshinone personalized therapy in Han Chinese.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31792370</pmid><doi>10.1038/s41397-019-0121-1</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-269X |
| ispartof | The pharmacogenomics journal, 2020-06, Vol.20 (3), p.408-414 |
| issn | 1470-269X 1473-1150 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2320873676 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | 45/23 45/77 631/154/1438 631/208/205 Abietanes - adverse effects Acne Adolescent Adult Adverse and side effects Aged Alleles Angina pectoris Anti-Infective Agents - adverse effects Antigens Asian Continental Ancestry Group - genetics Biomedical and Life Sciences Biomedicine Causes of Chinese medicine Complications and side effects Dermatology Drug Eruptions - diagnosis Drug Eruptions - genetics Drugs Female Gene Expression Genetic aspects Genetic Association Studies - methods Health aspects Histocompatibility antigen HLA Histocompatibility antigens HLA histocompatibility antigens HLA-A2 Antigen - genetics Hospitals Human Genetics Humans Ingredients Ligands Male Middle Aged Molecular Docking Simulation - methods Oncology Pharmacogenetics Pharmacology, Experimental Pharmacotherapy Population Population genetics Population Surveillance - methods Psychopharmacology Skin diseases Software Staphylococcus infections Tanshinones Young Adult |
| title | HLA-A02:01 allele is associated with tanshinone-induced cutaneous drug reactions in Chinese population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A57%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HLA-A02:01%20allele%20is%20associated%20with%20tanshinone-induced%20cutaneous%20drug%20reactions%20in%20Chinese%20population&rft.jtitle=The%20pharmacogenomics%20journal&rft.au=Zhu,%20Qinyuan&rft.date=2020-06-01&rft.volume=20&rft.issue=3&rft.spage=408&rft.epage=414&rft.pages=408-414&rft.issn=1470-269X&rft.eissn=1473-1150&rft_id=info:doi/10.1038/s41397-019-0121-1&rft_dat=%3Cgale_proqu%3EA625089834%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2407310915&rft_id=info:pmid/31792370&rft_galeid=A625089834&rfr_iscdi=true |